Comparative Analysis of 95 Patients with Different Severity in the Early Outbreak of COVID-19 in Wuhan, China
Table 4
Treatments and outcomes of COVID-19 patients.
Treatments and outcomes
All patients
Disease severity
value
Common
Severe
Critical
Number
95
54 (56.8)
27 (28.4)
14 (14.7)
NA
Treatment
HFNC
13 (13.7)
0 (0)
6 (22.2)
7 (50.0)
＜0.001
NIV
12 (12.6)
0 (0)
5 (18.5)
7 (50.0)
＜0.001
IV
5 (5.3)
0 (0)
0 (0)
5 (35.7)
＜0.001
Antiviral therapy
91 (95.8)
52 (96.3)
25 (92.6)
14 (100.0)
0.513
Abidol
41 (43.2)
20 (37.0)
14 (51.9)
7 (50.0)
0.382
Oseltamivir
31 (32.6)
18 (33.3)
7 (25.9)
6 (42.9)
0.541
Ganciclovir
33 (34.7)
17 (31.5)
10 (37.0)
6 (42.9)
0.697
Lopinavir plus ritonavir
55 (57.9)
32 (59.3)
15 (55.6)
8 (57.1)
0.949
Ribavirin
24 (25.3)
12 (22.2)
7 (25.9)
5 (35.7)
0.583
Interferon
14 (14.7)
5 (9.3)
5 (18.5)
4 (28.6)
0.155
Moxifloxacin∗
85 (89.5)
47 (87.0)
24 (88.9)
14 (100)
0.368
Levofloxacin
14 (14.7)
6 (11.1)
6 (22.2)
2 (14.3)
0.412
Linezolid
5 (5.3)
1 (1.9)
1 (3.7)
3 (21.4)
0.013
Piperacillin
20 (21.1)
8 (14.8)
10 (37.0)
2 (14.3)
0.055
Meropenem
6 (6.3)
0 (0)
4 (14.8)
2 (14.3)
0.015
Fluconazole
3 (3.2)
0 (0)
1 (3.7)
2 (14.3)
0.024
Glucocorticoids
32 (33.7)
11 (20.4)
12 (44.4)
9 (64.3)
0.003
Immunoglobulin
19 (20.0)
12 (22.2)
4 (14.8)
3 (21.4)
0.727
ICU admission
18 (18.9)
2 (3.7)
7 (25.9)
9 (64.3)
＜0.001
Days from hospital admission to ICU
6 (2–10)
NA
4 (1–8)
7.0 (3.0–11.5)
0.272
Outcome
Died
10 (10.5)
0 (0)
0 (0)
10 (71.4)
＜0.001
Improved and discharged
85 (89.5)
54 (100.0)
27 (100)
4 (28.6)
＜0.001
Days from hospitalization to discharge
19 (14.0–29.5)
16.5 (13.0–21.8）
28 (18–41)
NA
＜0.001
Days from hospitalization to death
18 (11–25)
NA
NA
18 (11–25)
NA
Data are presented as n (%) or medians (interquartile ranges, IQR). NA: not appropriate; HFNC, high-flow nasal cannula oxygen therapy; NIV, noninvasive ventilation; IV, invasive ventilation. ∗The usage of moxifloxacin in this table is the data of COVID-19 patients before admission.
